SCHEMBL14580998

SCHEMBL14580998

O=C1NC23NC(=O)NC2(N1)c1ccccc1-c1ccccc13

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ITGA4 P13612 1/20 0.55
▸ SMN1; SMN2 Q16637 1/20 0.50
▸ GSK3B P49841 1/20 0.44
▸ AKR1B1 P15121 4/20 0.44
▸ S100A4 P26447 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43
▸ AKR1A1 P14550 3/20 0.42
▸ THRB P10828 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ HSP90AA1 P07900 1/20 0.39
▸ HSP90AB1 P08238 1/20 0.39
▸ CASP3 P42574 1/20 0.38
▸ CASP2 P42575 1/20 0.38
▸ CASP7 P55210 1/20 0.38
▸ CASP6 P55212 1/20 0.38
▸ CASP8 Q14790 1/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ CDC25B P30305 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31195728 0.71 ITGA4 (1.00) ITGA4AKR1B1ALDH1A1AKR1A1TDP1
SCHEMBL9810959 0.71 ITGA4 (1.00) ITGA4AKR1B1ALDH1A1AKR1A1TDP1
SCHEMBL3973309 0.70 CYP2C9 (0.52) AKR1B1ALDH1A1THRBMEN1KMT2A
SCHEMBL22709486 0.69 SMN1; SMN2 (0.96) ITGA4SMN1; SMN2GSK3BS100A4ALDH1A1
SCHEMBL16626076 0.66 PDK2 (0.44) ITGA4SMN1; SMN2GSK3BS100A4ALDH1A1
SCHEMBL10602199 0.65 GSK3B (0.48) ITGA4SMN1; SMN2GSK3BAKR1B1S100A4
SCHEMBL357510 0.65 MEN1 (0.55) ITGA4SMN1; SMN2GSK3BS100A4ALDH1A1
SCHEMBL31598409 0.65 S100A4 (0.58) ITGA4SMN1; SMN2GSK3BS100A4ALDH1A1
SCHEMBL30833582 0.65 MEN1 (0.55) ITGA4SMN1; SMN2GSK3BS100A4ALDH1A1
SCHEMBL30501016 0.65 MEN1 (0.55) ITGA4SMN1; SMN2GSK3BS100A4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070037785-A1 Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases KEYNEUROTEK PHARMACEUTICALS AG (DE) 2007-02-15 — — US disclosed
US-20070037785-A1 Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases KEYNEUROTEK PHARMACEUTICALS AG (DE) 2007-02-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037785-A1 Novel dipeptidyl peptidase IV inhibitors used for functionally influencing different cells and treating immunological, infammatory, neuronal, and other diseases DNPEP, PREP, DPP4 ITGA4 3348/4885SMN1; SMN2 4098/4885GSK3B 1634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback